DUEXIS Drug Patent Profile

Which patents cover Duexis, and when can generic versions of Duexis launch?

Duexis is a drug marketed by Horizon and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

DrugPatentWatch^® Generic Entry Outlook for Duexis

There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for DUEXIS

International Patents:	25
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	154
Drug Prices:	Drug price information for DUEXIS
Drug Sales Revenues:	Drug sales revenues for DUEXIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DUEXIS
What excipients (inactive ingredients) are in DUEXIS?	DUEXIS excipients list
DailyMed Link:	DUEXIS at DailyMed

See drug prices for DUEXIS

See drug sales revenues for DUEXIS

Recent Clinical Trials for DUEXIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 4
Pediatric Rheumatology Collaborative Study Group	Phase 4

See all DUEXIS clinical trials

Paragraph IV (Patent) Challenges for DUEXIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUEXIS	Tablets	famotidine; ibuprofen	800 mg/26.6 mg	022519	1	2011-12-06

US Patents and Regulatory Information for DUEXIS

DUEXIS is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,067,451		Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,309,127		Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,501,228
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,318,202		Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,449,910		Y

International Patents for DUEXIS

When does loss-of-exclusivity occur for DUEXIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DUEXIS around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2438919	Compositions contenant de l'ibuprofene et de la famotidine ainsi que des compositions contenant de 25 mg a 28 mg de la famotidine (Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine)
European Patent Office	2043637	PROCÉDÉS ET MÉDICAMENTS DESTINÉS À L'ADMINISTRATION D'IBUPROFÈNE (METHODS AND MEDICAMENTS FOR ADMINISTRATION OF IBUPROFEN)
World Intellectual Property Organization (WIPO)	2007012022
Canada	2657928
Austria	E539747
New Zealand	565846	Medicaments containing famotidine and ibuprofen and administration of same
Poland	2043637

Market Dynamics and Financial Trajectory for DUEXIS

Last updated: January 3, 2026

Executive Summary

DUEXIS (ibuprofen/famotidine) is a combination drug approved by the U.S. Food and Drug Administration (FDA) for managing osteoarthritis and rheumatoid arthritis pain while reducing gastrointestinal (GI) side effects. Since its launch, DUEXIS has carved a niche within the anti-inflammatory and gastroprotective segments, though its market share remains relatively modest given the presence of dominant NSAID therapies and alternative GI protectants. This report examines the current market landscape, competitive positioning, key financial metrics, and future growth drivers for DUEXIS, offering comprehensive insights for stakeholders and investors.

---

What Are the Market Drivers for DUEXIS?

Pharmacological Profile and Medical Need

DUEXIS combines ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), with famotidine, an H2 receptor antagonist, aiming to mitigate NSAID-induced gastrointestinal injuries. The co-prescription of NSAIDs with gastroprotectants is standard, but fixed-dose combinations offer improved adherence and convenience.

Addressable Patient Population

• Osteoarthritis and Rheumatoid Arthritis (RA): Estimated at 54 million Americans with osteoarthritis, 1.3 million with RA (CDC, 2022).
• NSAID Use: NSAIDs are front-line therapies, with over 30 million prescriptions annually in the U.S. (IQVIA, 2022).
• GI Complication Risks: Up to 25% of chronic NSAID users experience GI ulcers or bleeding (Goldstein et al., 2018).

Regulatory and Prescribing Trends

• Increased awareness of GI side effects has promoted co-therapy with gastroprotectants.
• FDA guidelines encourage minimizing NSAID-related GI risks, favoring fixed-dose combinations like DUEXIS.

Key Market Trends

Trend	Impact on DUEXIS
Shift towards combination therapies	Facilitates adoption of fixed-dose drugs like DUEXIS.
Patient preference for simplified regimens	Enhances adherence and market appeal.
Rising chronic NSAID use	Expands overall market but intensifies GI complication management.

---

What Is the Current Market Position of DUEXIS?

Sales Performance and Market Share

Year	Estimated U.S. Sales (USD millions)	Market Share (NSAID + gastroprotectant segment)
2018	$45 million	2.5%
2019	$48 million	2.6%
2020	$42 million	2.2%
2021	$40 million	2.0%

Data based on IQVIA and Vertical Research Partners.

Pricing and Reimbursement

• Average Wholesale Price (AWP): Approximately $2.80 per tablet.
• Insurance Coverage: Favorable, with high formulary inclusion rates owing to its safety profile.

Distribution Channels

• Predominantly prescribed via primary care and rheumatology specialists.
• Available through outpatient pharmacies and specialty dispensing programs.

---

Who Are the Main Competitors and Substitutes?

Competitor	Product	Marketed As	Key Differentiators	Estimated Sales (USD millions, 2022)
Voltaren (diclofenac)	Diclofenac topical	Topical NSAID	Non-systemic, localized delivery	$150
Aleve (naproxen)	Naproxen	OTC NSAID	Over-the-counter ease	$500+
Cytotec (misoprostol)	Misoprostol	GI protectant	Alternative, not fixed-dose combo	Variable
Other NSAID/Gastroprotectant Combinations	Various	Similar formulations	Differentiation based on dosing	Limited

Unique Selling Proposition (USP) of DUEXIS

• Fixed-dose combination enhances compliance.
• Preserved anti-inflammatory efficacy of ibuprofen.
• Simultaneous GI risk mitigation via famotidine.

---

What Are the Key Financial Metrics and Growth Drivers?

Revenue Projections

Year	Projected U.S. Sales (USD millions)	Assumptions
2023	$38 million	Stable prescribing patterns, limited promotional efforts
2025	$45 million	Increased physician awareness, slight market growth
2030	$60+ million	Potential uptake in chronic care programs and expanded indications

Profitability Outlook

• Gross Margins: Estimated at 55-60%, reflective of branded drug positioning.
• Investment in Promotion: Moderate, focusing on rheumatology and primary care channels.
• Pricing Strategies: Slight premium over generic NSAIDs given added safety benefits.

Growth Drivers

1. Expanding Indications: Potential label expansions into broader NSAID-related pain management.
2. Partnerships and Collaborations: Alliances with payers and healthcare providers to promote fixed-dose regimens.
3. Patent and Exclusivity Status: Patent exclusivity expected until 2025, after which generics may challenge.

---

How Do Market Dynamics Affect DUEXIS?

Regulatory Environment

• FDA Guidance: Emphasizes safety and combination therapy optimization.
• Patent Expiry: Patent protection until 2025 offers a temporary monopoly.

Reimbursement Policies

• Favorability of pharmacoeconomic studies demonstrating reduced hospitalization costs due to fewer GI complications.
• Payer incentives for adherence-enhancing fixed-dose combinations.

Economic and Healthcare Trends

• Growing prevalence of chronic NSAID use.
• Increasing healthcare expenditure on managing adverse drug reactions.
• Pressure to contain costs prompts preference for cost-effective therapies.

Market Risks and Challenges

Risk	Impact	Mitigation Strategies
Market penetration stagnation	Limited revenue growth	Enhanced prescribing campaigns
Competition from OTC NSAIDs	Reduced physician scripts	Emphasize safety profile & adherence benefits
Patent expiration	Generic entry	Diversify indications, optimize branding

---

What Are the Future Opportunities for DUEXIS?

Expansion of Indications

• Rheumatology and pain clinics exploring broader NSAID-related pain management.
• Potential for use in postoperative pain regimens with GI protection components.

Formulation and Delivery Innovations

• Development of extended-release formulations.
• New fixed-dose combinations targeting other GI protective agents.

Market Penetration Strategies

• Education campaigns highlighting safety benefits.
• Collaboration with health authorities and payers for formulary inclusion.
• Targeted marketing to specialists and primary care providers.

---

Comparison Table: DUEXIS vs. Competitors

Attribute	DUEXIS	Voltaren	OTC NSAIDs	Misoprostol (Cytotec)
Ingredient	Ibuprofen + Famotidine	Diclofenac	Ibuprofen, Naproxen	Misoprostol
Formulation	Fixed-dose	Topical, oral	OTC tablets	Capsule
Indication	Osteoarthritis, RA with GI protection	Pain/inflammation	Pain relief	GI ulcer prevention
Cost (USD)	~$2.80/tablet	~$0.20/tablet	~$0.05-0.50/ OTC	$10-20 per prescription
Patent Status	Valid until 2025	Expired	Generic available	Patented

---

Conclusion: Strategic Outlook and Investment Considerations

DUEXIS operates within a nuanced landscape where its value proposition—combining NSAID efficacy with GI safety—aligns with evolving prescriber and payer priorities. The drug’s potential hinges on patent protections remaining until 2025, after which generic competition could dilute margins. Nevertheless, the growing need for safer NSAID therapies, coupled with healthcare reforms favoring fixed-dose combinations, sustains its relevance.

The primary growth avenues include broader indication scopes, enhanced educational outreach, and formulation innovations. Stakeholders investing or collaborating should focus on consolidation before patent expiration and leveraging the increasing emphasis on safe, adherence-promoting therapies.

---

Key Takeaways

• Market Niche: DUEXIS provides an evidence-backed, patient-centric NSAID with added GI safety, aligning with regulatory trends.
• Growth Drivers: Indication expansion, payer interest, and adherence advantages underpin future growth potential.
• Challenges: Patent expiry in 2025, competitive generics, and market penetration stagnation pose risks.
• Financial Outlook: Moderate revenue growth projected through 2025, with profitability maintained via premium positioning.
• Strategic Recommendations: Prioritize patent-protected marketing, explore new indications, and innovate formulation strategies.

---

FAQs

1. How does DUEXIS differentiate itself from generic NSAIDs?
   DUEXIS’s fixed-dose combination with famotidine reduces GI adverse events associated with NSAIDs and enhances patient adherence, offering a safety profile that generics lack.

2. What is the patent status of DUEXIS?
   Patent protection is valid until 2025, after which generics are expected to enter the market, potentially impacting revenue.

3. Are there any regulatory hurdles for expanding DUEXIS indications?
   Yes, new indications require clinical trials and regulatory approval, which can be time-consuming and costly but may expand market potential.

4. What is the potential for global market expansion?
   Currently limited; future opportunities may emerge in markets with similar prescribing patterns and regulatory frameworks, contingent on approvals and reimbursement policies.

5. How does reimbursement influence DUEXIS’s market performance?
   Favorable reimbursement, driven by pharmacoeconomic evidence, facilitates formulary placement and encourages prescribing, thus supporting sales growth.

---

References

[1] Centers for Disease Control and Prevention (CDC). (2022). Osteoarthritis Data.
[2] IQVIA. (2022). U.S. Prescription Data.
[3] Goldstein, J. L., et al. (2018). “NSAID-Induced Gastrointestinal Injury.” Gastroenterology, 154(3), 651-660.
[4] Vertical Research Partners. (2022). Market Analysis Reports.
[5] FDA. (2019). Guidance for Industry: Fixed-Dose Combination Drugs.